The Chemours (NYSE:CC) posted its earnings results on Sunday. The specialty chemicals company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.08, MarketWatch Earnings reports. The Chemours had a positive return on equity of 46.27% and a negative net margin of 2.35%. The company had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the business earned $0.71 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis.
CC traded up $0.52 during trading on Tuesday, hitting $31.53. 1,329,176 shares of the stock were exchanged, compared to its average volume of 1,455,070. The Chemours has a 1 year low of $10.62 and a 1 year high of $32.21. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of -43.07 and a beta of 2.30. The firm has a 50 day simple moving average of $28.53 and a 200 day simple moving average of $26.06. The company has a debt-to-equity ratio of 5.54, a quick ratio of 1.23 and a current ratio of 1.99.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 15th. Investors of record on Monday, May 17th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, May 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 3.17%. The Chemours’s payout ratio is 39.84%.
A number of equities analysts have commented on the stock. Morgan Stanley lifted their price objective on shares of The Chemours from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 16th. BMO Capital Markets upped their price objective on The Chemours from $33.00 to $38.00 in a research report on Tuesday, February 16th. Royal Bank of Canada upgraded The Chemours from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $27.00 to $35.00 in a report on Friday, January 8th. Finally, Citigroup increased their price target on The Chemours from $27.00 to $29.00 in a report on Wednesday, February 17th. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $26.67.
The Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications.
Featured Article: Capital Gains
Receive News & Ratings for The Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours and related companies with MarketBeat.com's FREE daily email newsletter.